Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region.

Autor:	Anadkat MJ; Division of Dermatology, Department of Medicine, Washington University, St. Louis, MO, United States., Lacouture M; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States., Friedman A; Division of Dermatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, United States., Horne ZD; Department of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, United States., Jung J; Department of Dermatology, Norton Healthcare, Louisville, KY, United States., Kaffenberger B; Wexner Medical Center, Ohio State University, Columbus, OH, United States., Kalmadi S; Oncology and Haematology Department, Ironwood Cancer & Research Center, Chandler, AZ, United States., Ovington L; Ovington & Associates, Walnutport, PA, United States., Kotecha R; Miami Cancer Institute, Baptist Health South Florida, Miami, FL, United States., Abdullah HI; Novocure Inc., New York, NY, United States., Grosso F; Mesothelioma Unit, SS Antonio e Biagio General Hospital, Alessandria, Italy.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2023 Jan 04; Vol. 12, pp. 975473. Date of Electronic Publication: 2023 Jan 04 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.975473
Abstrakt:	Tumor Treating Fields (TTFields) are electric fields, delivered via wearable arrays placed on or near the tumor site, that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. As a first-in-class treatment, TTFields therapy is approved for use in newly diagnosed glioblastoma, recurrent glioblastoma, and pleural mesothelioma. Additionally, TTFields therapy is being investigated in non-small cell lung cancer (NSCLC), brain metastases from NSCLC, pancreatic cancer, ovarian cancer, hepatocellular carcinoma, and gastric adenocarcinoma. Because TTFields therapy is well tolerated and delivery is locoregional, there is low risk of additive systemic adverse events (AEs) when used with other cancer treatment modalities. The most common AE associated with TTFields therapy is mild-to-moderate skin events, which can be treated with topical agents and may be managed without significant treatment interruptions. Currently, there are no guidelines for oncologists regarding the management of TTFields therapy-related skin AEs in the thoracic region, applicable for patients with pleural mesothelioma or NSCLC. This publication aims to provide guidance on preventing, minimizing, and managing dermatologic AEs in the thoracic region to help improve patient quality of life and reduce treatment interruptions that may impact outcomes with TTFields therapy. Competing Interests: MJA reports personal fees as a past consultant for ImClone, Bristol Myers Squibb, AstraZeneca, Therakos, Aspire Bariatrics, Biogen, Amgen, Veloce, Adgero, Eli Lilly, AbbVie, UCB Biopharma, OnQuality Pharmaceuticals, and Innovaderm Research. MJA is an advisor and/or consultant for Boehringer-Ingelheim, OnQuality Pharmaceuticals, Novocure, Springworks Therapeutics, BioLinq, and Protagonist. ML reports personal fees as a consultant for Johnson & Johnson, Novocure, QED, Bicara Therapeutics, Janssen, Novartis, F. Hoffmann-La Roche AG, EMD Serono, AstraZeneca, Innovaderm Research, Deciphera, DFB Pharmaceuticals, Azitra, Kintara Therapeutics, La Roche-Posay, Trifecta Pharmaceuticals, Varsona Therapeutics, Genentech, Loxo Oncology, Seagen, Lutris Pharma, OnQuality Pharmaceuticals, Oncoderm Labs, NCODA, and Apricity Therapeutics. ML has received funding for research from Lutris Pharma, Paxman, Novocure, Johnson & Johnson, US Biotest, OQL, Novartis, and AstraZeneca. ML has received grant funding from the NIH/NCI Cancer Center Support (Grant P30 CA008748). AF reports personal fees as a consultant for L'Oréal, La Roche-Posay, Galderma, Aveeno, MicroCures, Pfizer, Novartis, Menlo Therapeutics, Incyte, Eli Lilly, MINO Labs, Dermira, Zylö Therapeutics, Hoth Therapeutics, Corbus Pharmaceuticals, FSD pharma, Regeneron, Sanofi, AbbVie, Insed, Brickell Biotech, and UCB. AF has received grant funding from Pfizer, Galderma, and Incyte. AF reports honoraria from Incyte, Janssen, AbbVie, Regeneron, and UCB. ZH reports personal fees as a consultant for Novocure, AstraZeneca, Regeneron, and Sanofi Genzyme. ZH has received honoraria from Novocure. JJ reports honoraria from Regeneron and Sanofi. BHK reports personal fees as a consultant for Novocure, Novartis, and Eli Lilly. BHK is an investigator for Biogen, Janssen, OnQuality Pharmaceuticals, Merck, and InflaRx. SK reports funding for research from Novocure, Bristol Myers Squibb, Novartis, Janssen, and AstraZeneca. SK reports personal fees as a consultant for Janssen, F. Hoffmann-La Roche AG, Novartis, Pfizer, AstraZeneca, and TG therapeutics. LO reports personal fees as a consultant for Ethicon Inc. RK reports personal fees as a consultant for Accuray, Elekta, ViewRay, Novocure, Elsevier, and Brainlab. LO reports institutional research funding from Medtronic, Blue Earth Diagnostics Ltd, Novocure, GT Medical Technologies, AstraZeneca, Exelixis, ViewRay, and Brainlab. HA is an employee of Novocure and holds stocks in Novocure. FG reports personal fees for advisory roles, speaker engagements, and travel and accommodation expenses from Merck, Novocure, Bristol Myers Squibb, Boehringer Ingelheim, PharmaMar, Novartis, and Pierre Fabre. Writing and editorial support provided by Prime was funded by Novocure Inc. and conducted according to Good Publication Practice guidelines (Link). (Copyright © 2023 Anadkat, Lacouture, Friedman, Horne, Jung, Kaffenberger, Kalmadi, Ovington, Kotecha, Abdullah and Grosso.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu